Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.

Trial Details

NCT ID

NCT04822337

Phase

PHASE1 / PHASE2

Sponsor

Wake Forest University Health Sciences

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

Locations (sample)

Charlotte, North Carolina, United States|35.22709,-80.84313
Winston-Salem, North Carolina, United States|36.09986,-80.24422

Key Eligibility Criteria

Written informed consent and HIPAA authorization for release of personal health information signed by the subject or his/her legally authorized rep…
Age greater than or equal to 18 years at the time of consent. Because no dosing or adverse event data are currently available on the use of belanta…
ECOG Performance Status of less than or equal to 2
Demonstrate adequate organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →